These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 32769561

  • 1. Isolated Central Nervous System Progression During Systemic Treatment With Brentuximab Vedotin Monotherapy in a Pediatric Patient With Recurrent ALK-negative Anaplastic Large Cell Lymphoma.
    Kim Y, Sudo A, Oyama R, Keino D, Tomizawa D, Kato M, Osumi T, Mori T.
    J Pediatr Hematol Oncol; 2021 Aug 01; 43(6):e864-e866. PubMed ID: 32769561
    [Abstract] [Full Text] [Related]

  • 2. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
    Agrusa JE, Egress ER, Lowe EJ.
    Front Immunol; 2023 Aug 01; 14():1203471. PubMed ID: 37275877
    [Abstract] [Full Text] [Related]

  • 3. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series.
    Ruf S, Hebart H, Hjalgrim LL, Kabickova E, Lang P, Steinbach D, Schwabe GC, Woessmann W.
    Pediatr Blood Cancer; 2018 Jun 01; 65(6):e27003. PubMed ID: 29512859
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ, Everett E, Zhang X, Nagaraj G.
    Expert Rev Anticancer Ther; 2016 Jun 01; 16(3):279-83. PubMed ID: 26809026
    [Abstract] [Full Text] [Related]

  • 7. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
    Lowe EJ, Reilly AF, Lim MS, Gross TG, Saguilig L, Barkauskas DA, Wu R, Alexander S, Bollard CM.
    Blood; 2021 Jul 01; 137(26):3595-3603. PubMed ID: 33684925
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease.
    Mitsunobu T, Nishikawa T, Kusuda M, Nakagawa S, Kodama Y, Okamoto Y, Kawano Y.
    J Pediatr Hematol Oncol; 2020 Aug 01; 42(6):e456-e458. PubMed ID: 31274669
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
    Halligan SJ, Grainge MJ, Martinez-Calle N, Fox CP, Bishton MJ.
    Br J Haematol; 2022 Feb 01; 196(4):932-938. PubMed ID: 34664265
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
    Chihara D, Wong S, Feldman T, Fanale MA, Sanchez L, Connors JM, Savage KJ, Oki Y.
    Hematol Oncol; 2019 Feb 01; 37(1):35-38. PubMed ID: 30209819
    [Abstract] [Full Text] [Related]

  • 18. Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.
    Aguiar-Bujanda D, Dueñas-Comino A, Cabello C, Bastida J, Rivero-Vera JC, Limeres-González MA.
    Eur J Dermatol; 2017 Dec 01; 27(6):671-673. PubMed ID: 29165301
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.